Effect of uric acid levels on mortality in Japanese peritoneal dialysis patients.


Journal

Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis
ISSN: 1718-4304
Titre abrégé: Perit Dial Int
Pays: United States
ID NLM: 8904033

Informations de publication

Date de publication:
05 2021
Historique:
pubmed: 6 6 2020
medline: 25 11 2021
entrez: 6 6 2020
Statut: ppublish

Résumé

Unlike the situation in the general population, most studies of patients receiving hemodialysis have reported lower uric acid (UA) as associated with higher mortality. However, the relationship between UA level and mortality remains unclear among patients receiving peritoneal dialysis (PD). We collected baseline data for 4742 prevalent PD patients (age, 63 ± 14 years; male, 61.5%; diabetes, 29.1%; median dialysis duration, 28 months) from a nationwide dialysis registry in Japan at the end of 2012. One-year all-cause and cardiovascular (CV) mortality and mortality caused by infectious disease were assessed using Cox regression analysis and competing-risks regression analysis, respectively. We used multiple imputation to deal with missing covariate data. Within 1 year, 379 patients (8.0%) died, including 129 patients (2.7%) from CV causes and 95 patients (2.0%) from infectious disease. In multivariate analysis, serum UA, treated as a continuous variable, was not associated with any outcome. Conversely, both lower (<297 µmol/L) and higher (≥476 µmol/L) UA levels were independently associated with higher all-cause mortality compared to the reference group (416 to <446 µmol/L) in analyses where serum UA was treated as a categorical variable. Body mass index (BMI) affected the association between serum UA and all-cause mortality (interaction A U-shaped relationship appears to exist between UA levels and all-cause mortality among Japanese PD patients. Additionally, lower BMI significantly enhanced the effect of UA levels on mortality.

Sections du résumé

BACKGROUND
Unlike the situation in the general population, most studies of patients receiving hemodialysis have reported lower uric acid (UA) as associated with higher mortality. However, the relationship between UA level and mortality remains unclear among patients receiving peritoneal dialysis (PD).
METHODS
We collected baseline data for 4742 prevalent PD patients (age, 63 ± 14 years; male, 61.5%; diabetes, 29.1%; median dialysis duration, 28 months) from a nationwide dialysis registry in Japan at the end of 2012. One-year all-cause and cardiovascular (CV) mortality and mortality caused by infectious disease were assessed using Cox regression analysis and competing-risks regression analysis, respectively. We used multiple imputation to deal with missing covariate data.
RESULTS
Within 1 year, 379 patients (8.0%) died, including 129 patients (2.7%) from CV causes and 95 patients (2.0%) from infectious disease. In multivariate analysis, serum UA, treated as a continuous variable, was not associated with any outcome. Conversely, both lower (<297 µmol/L) and higher (≥476 µmol/L) UA levels were independently associated with higher all-cause mortality compared to the reference group (416 to <446 µmol/L) in analyses where serum UA was treated as a categorical variable. Body mass index (BMI) affected the association between serum UA and all-cause mortality (interaction
CONCLUSIONS
A U-shaped relationship appears to exist between UA levels and all-cause mortality among Japanese PD patients. Additionally, lower BMI significantly enhanced the effect of UA levels on mortality.

Identifiants

pubmed: 32500808
doi: 10.1177/0896860820929476
doi:

Substances chimiques

Uric Acid 268B43MJ25

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

320-327

Auteurs

Naoki Sugano (N)

Division of Nephrology and Hypertension, Department of Internal Medicine, 12839The Jikei University School of Medicine, Tokyo, Japan.

Yukio Maruyama (Y)

Division of Nephrology and Hypertension, Department of Internal Medicine, 12839The Jikei University School of Medicine, Tokyo, Japan.
Committee of Renal Data Registry, Japanese Society for Dialysis Therapy, Tokyo, Japan.

Iwao Ohno (I)

Division of General Medicine, Department of Internal Medicine, 12839The Jikei University School of Medicine, Tokyo, Japan.

Atsushi Wada (A)

Committee of Renal Data Registry, Japanese Society for Dialysis Therapy, Tokyo, Japan.

Takashi Shigematsu (T)

Committee of Renal Data Registry, Japanese Society for Dialysis Therapy, Tokyo, Japan.

Ikuto Masakane (I)

Committee of Renal Data Registry, Japanese Society for Dialysis Therapy, Tokyo, Japan.

Takashi Yokoo (T)

Division of Nephrology and Hypertension, Department of Internal Medicine, 12839The Jikei University School of Medicine, Tokyo, Japan.

Kosaku Nitta (K)

Committee of Renal Data Registry, Japanese Society for Dialysis Therapy, Tokyo, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH